Last reviewed · How we verify
Vitamin K Antagonist - Drug
At a glance
| Generic name | Vitamin K Antagonist - Drug |
|---|---|
| Also known as | direct oral anticoagulant |
| Sponsor | Onze Lieve Vrouw Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation (PHASE4)
- A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)
- Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Heart Valve Replacement (PHASE4)
- Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus (PHASE3)
- Amplatzer Amulet LAAO vs. NOAC (NA)
- Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS
- The Study of CYP2C19 Genotype-Guided Clopidogrel Treatment Models (NA)
- Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vitamin K Antagonist - Drug CI brief — competitive landscape report
- Vitamin K Antagonist - Drug updates RSS · CI watch RSS
- Onze Lieve Vrouw Hospital portfolio CI